International journal of molecular medicineJul 10, 2026

Hormone and metabolism imbalance may contribute to osteoarthritis: From joint changes to targeted treatments

Longevity & Aging Weekly Brief ↗PubMed ↗DOI ↗

Updated Jul 14, 2026

Abstract

Osteoarthritis (OA) is characterized by cartilage degeneration and is increasingly recognized as a whole-joint disorder influenced by metabolic dysfunction.

OA involves chronic joint degeneration, inflammation, and functional impairment linked to aging and metabolic issues.
Endocrine factors such as sex hormones, thyroid hormone, and vitamin D may interact with metabolic disturbances like obesity and insulin resistance to affect joint health.
These interactions could lead to increased inflammation, oxidative stress, and cellular aging, contributing to joint damage.
Current understanding of the interplay between endocrine signals and joint pathology is limited and requires further investigation.
Targeting the hormonal and metabolic factors may provide new opportunities for personalized treatment approaches in OA.

Simplified

Osteoarthritis (OA) is a chronic degenerative joint disease closely associated with aging and metabolic dysfunction, characterized by cartilage degeneration, synovial inflammation, aberrant subchondral bone remodeling, pain and progressive functional impairment. Beyond mechanical loading, accumulating evidence indicates that OA is increasingly recognized as a whole‑joint disorder shaped by the interplay between local tissue damage and systemic endocrine‑metabolic imbalance. Endocrine factors, including sex hormones, thyroid hormone, melatonin, parathyroid hormone and vitamin D, together with metabolic disturbances, such as obesity, insulin resistance, dysregulated glucose and lipid metabolism and gut microbiota imbalances, can cooperatively remodel the joint microenvironment. Mechanistically, these alterations converge on immuno‑inflammatory amplification, mitochondrial dysfunction, oxidative stress, cellular senescence, metabolic reprogramming and regulated cell death, thereby promoting extracellular matrix degradation, persistent synovitis and uncoupled bone‑cartilage remodeling. The present review systematically summarizes the molecular basis of endocrine‑metabolic crosstalk in OA and discusses emerging therapeutic opportunities targeting hormonal signaling, metabolic pathways, circadian regulation, nutritional support and lifestyle interventions. Nevertheless, the reciprocal interactions among endocrine signals, systemic metabolic abnormalities and local joint pathology remain incompletely understood, and their translation into mechanism‑based clinical stratification remains at an early stage. Thus, targeting endocrine‑metabolic crosstalk may support mechanism‑based phenotyping and subtype‑informed precision therapy for OA, provided that candidate biomarkers and interventions are validated in prospective clinical studies.

Hormone and metabolism imbalance may contribute to osteoarthritis: From joint changes to targeted treatments

Abstract

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the longevity & aging brief

Abstract

Related papers

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the longevity & aging brief